echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Diabetes drug market: Eli Lilly and Novo Nordisk compete fiercely, Sanofi exits

    Diabetes drug market: Eli Lilly and Novo Nordisk compete fiercely, Sanofi exits

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Due to the change of lifestyle and the acceleration of the aging process, the number of patients with type 2 diabetes in the world is increasing, and the corresponding therapeutic drug field has also become a huge market.

    The GLP-1RA dispute between Eli Lilly and Novo Nordisk

    The GLP-1RA dispute between Eli Lilly and Novo Nordisk

    The main competitors in the field of GLP-1 receptor agonists are Eli Lilly and Novo Nordisk.


    GLP-1 drug sales

    Eli Lilly’s next type 2 diabetes pipeline's blockbuster product will be Tirzepatide, which has now issued a strong challenge to semaglutide.

    On March 4, 2021, Eli Lilly's Phase III clinical Tizepatide and Semaglutide head-to-head comparison of SURPASS-2 was successful.

    SURPASS-2 test results

    All three test doses of Tirzepatide can significantly reduce blood sugar levels and body weight.

    When diabetes drugs are not just for diabetes

    When diabetes drugs are not just for diabetes

    Novo Nordisk's main income comes from insulin, including quick-acting, long-acting and pre-mixed drugs, followed by GLP-1 drugs, but insulin sales have declined, partly because of the price drop and the new US legislation forcing the company to pay for medical insurance.

    Somaglutide is considered to be the strongest GLP-1RA, and Novo Nordisk will further explore its greater potential.

    Novo Nordisk's GLP-1 drug development plan

    Novo Nordisk's GLP-1 drug development plan

    In addition, in the field of diabetes, PIONEER series of trials will continue, among which PIONEER Plus explores high-dose semaglutide 25mg and 50mgQD, SUSTAIN FORTE explores high-dose semaglutide injection 2mg QW, and also launched FOCUS The effect of marutide subcutaneous injection on diabetic retinopathy in T2D patients.

    Relevant indications are also being explored drastically, and large-scale clinical trials are carried out for patients with diabetes and other diseases, including type 2 diabetes patients with cardiovascular events or chronic kidney disease, and a large-scale SOUL enrolling nearly 10,000 people is carried out.

    For other non-diabetic diseases, the SELECT trial includes non-diabetic obese patients, a phase III trial for early Alzheimer's patients will also start, and the NASH trial is expected to start in 2021.

    Leave and expand

    Leave and expand

    Sanofi announced in December 2019 that after the new CEO took office, it would stop research on new diabetes and cardiovascular drugs and turn to the fields of autoimmunity and oncology.

    2020 sales of major products in the field of type 2 diabetes

    It can be seen from the sales list that in addition to GLP-1 drugs, the sales of two SGLT-2 inhibitors have increased greatly, thanks to the expansion of the two in heart failure indications.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.